Please use this identifier to cite or link to this item: http://hdl.handle.net/10603/356773
Full metadata record
DC FieldValueLanguage
dc.coverage.spatial
dc.date.accessioned2022-01-19T07:32:01Z-
dc.date.available2022-01-19T07:32:01Z-
dc.identifier.urihttp://hdl.handle.net/10603/356773-
dc.description.abstractDissolution rate is the limiting step in the absorption of water insoluble drugs (Both BCS newlineClass II and Class IV drugs) which in turn limits the therapeutic efficacy. The challenge for newlinethese drugs is to enhance the rate of dissolution without impacting their permeability. newlineHence, the present investigation was aimed to improve the bioavailability of insoluble newlinedrugs Olmesartan Medoxomil (BCS Class II) and Azilsartan Medoxomil (BCS Class IV) newlineby two novel lipid based approaches such as Lipid Base Liquisolid Compaction and Lipid newlineBased Solid Dispersions. Formulations of both the drugs prepared by liquisolid compaction newlineand solid dispersion have shown enhanced drug release compared to pure drug. More newlineimprovement in dissolution rate was observed with lipid based liquisolid compaction than newlinelipid based solid dispersion. This might be due to the presence of liquid inside the newlineformulation which might be acted as co-solvent. In support of in vitro dissolution studies, newlineEx Vivo goat intestinal permeability studies performed were also revealed that the liquisolid newlineformulations have shown greater drug diffusion than remaining formulations. In Vivo newlinestudies revealed that bioavailability of final optimized formulations of both the drugs was newlinehigher than the marketed formulation as well as pure drug. Hence, it can be concluded that, newlineliquisolid technique would be a promising approach in improving dissolution rate and newlinehence the bioavailability of water insoluble drugs such as Olmesartan and Azilsartan newline
dc.format.extentxii,144
dc.languageEnglish
dc.relation
dc.rightsuniversity
dc.titleLipid based drug delivery system to enhance the oral bioavailability of olmesartan and azilsartan
dc.title.alternative
dc.creator.researcherChopra,Dhiraj Kumar
dc.subject.keywordClinical Pre Clinical and Health
dc.subject.keywordPharmacology and Toxicology
dc.subject.keywordSubstance Abuse drugs
dc.description.note
dc.contributor.guidePanigrahi,Lalatendu and Durga Madhab Kar
dc.publisher.placeBhubaneswar
dc.publisher.universitySiksha quotOquot Anusandhan University
dc.publisher.institutionDepartment of Pharmaceutics
dc.date.registered
dc.date.completed2020
dc.date.awarded
dc.format.dimensions
dc.format.accompanyingmaterialDVD
dc.source.universityUniversity
dc.type.degreePh.D.
Appears in Departments:Department of Pharmaceutics

Files in This Item:
File Description SizeFormat 
01_title.pdfAttached File263.94 kBAdobe PDFView/Open
02-declaration.pdf181.6 kBAdobe PDFView/Open
03_certificate.pdf271.3 kBAdobe PDFView/Open
04_acknowledgement.pdf213.96 kBAdobe PDFView/Open
05_contents.pdf188.42 kBAdobe PDFView/Open
06_list of figures and table.pdf217.07 kBAdobe PDFView/Open
07_chapter 1.pdf1.55 MBAdobe PDFView/Open
08_chapter 2.pdf449.23 kBAdobe PDFView/Open
09_chapter 3.pdf308.55 kBAdobe PDFView/Open
10_chapter 4.pdf560.54 kBAdobe PDFView/Open
11_chapter 5.pdf366.17 kBAdobe PDFView/Open
12_chapter 6.pdf608.84 kBAdobe PDFView/Open
13_chapter 7.pdf3.89 MBAdobe PDFView/Open
14_chapter 8.pdf320.05 kBAdobe PDFView/Open
15_bibliography.pdf286.07 kBAdobe PDFView/Open
80_recommendation.pdf174.43 kBAdobe PDFView/Open


Items in Shodhganga are licensed under Creative Commons Licence Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0).

Altmetric Badge: